{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349157","form_type":"8-K/A","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2026-08-13T20:06:20+00:00","discovered_at":"2026-08-13T20:09:04.456747+00:00","generated_at":"2026-08-13T20:09:51.834300+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RenovoRx Q2 revenue $909k, up 115% YoY; raises FY26 guidance to $3.75-4.25M","bullets":["Q2 2026 revenue $909k, up 61% QoQ and 115% YoY; gross margin 84.3%.","FY2026 revenue guidance raised to $3.75M-$4.25M from prior $3.0M-$4.0M.","Phase III TIGeR-PaC fully enrolled; completion expected H1 2027, topline H2 2027.","First commercial RenovoCath use in sarcoma; active cancer centers up to 21 from 16.","Net loss $2.9M ($0.06/share); cash $9.5M, sufficient into H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349157","json":"https://secwatch.observer/filing/0001193125-26-349157.json","markdown":"https://secwatch.observer/filing/0001193125-26-349157.md","text":"https://secwatch.observer/filing/0001193125-26-349157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526349157/0001193125-26-349157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000119312526349157/rnxt-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:09:51.834300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}